Quality of life of patient with schizophrenia treated by conventional and atypical neuroleptics;Qualité de vie chez les patients atteints de schizophrènie traités par neuroleptiques classiques et atypiques

Tunisie Medicale

Volumn 87, Issue 9, 2009, Pages 593-598

  Zaghdoudi, Lilia ^a   Homri, W ^a   Belaid, S ^a   Bechir M, Ben ^a   Labbane, Raja ^a  

^a RAZI HOSPITAL   (Tunisia)

Author keywords

Neuroleptics; Quality of life; Schizophrenia; Social adaptation

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; OUTCOMES RESEARCH; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; SCHIZOPHRENIA; SCORING SYSTEM; SHORT FORM 36; SOCIAL ADAPTATION; TREATMENT OUTCOME;

EID: 77649214707     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Awed AG. A conceptual model of quality of life in schizophrenia. Qual Life Res 1997; 6: 21-6.
2. AwadAG, Vorganti LNP. Quality of life and new antipsychotics in schizophrenia are patients better off?. International Journal of Social Psychiatry 1999; 45: 268-75.
3. AwadAG, Vorganti LNP. New Antipsychotics, Compliance, Quality of life, and Subjective. Tolerability- Are patients better off?. Can J Psychiatry 2004; 49:297-301.
4. Bond GR, Meyer PS. The role of medications in the employment of people with schizophrenia. Journal of Rehabilitation 1999; 65 : 9 16.
5. Bradshaw W, Brekke JS. Subjective experience in schizophrenia: Factors influencing self-esteem, satisfaction with life, and subjective distress. Am J Orthopsychiatry 1999; 69:254-60.
6. Caci H. Antipsychotiques, neuroleptiques et qualité de vie. Halopsy 1998 ; 19-23-4.
7. Carriere P, Bonhomme D, Lemperiere L. Meilleur rapport bénéfice / risque de l'amisulpiride comparé à l'halopéridol dans la schizophrénie : résultats d'une étude multicentrique en double aveugle (groupe d́tude de l'amisulpride ) . Eur Psychiatry2000 ; 15 : 321-6.
8. Chouinard G, Margolese HC. Manual for Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Res 2005; 76: 247-65.Errratum in : Schizophrenia Res 2006; 85:305.
9. Colonna L, Saleem P, Doney Nouvil L, Rein W. Tolérance et efficacité à long terme de l'amisulpiride dans la schizophrénie chronique ou subchronique . International Clinical Psychopharmacology 2000 ; 15 ;13-22.
10. Chambon O, Marie-Cardine M, Cottraux J et al. Impact d'un programme global d'entraînement aux habilités sociales sur le fonctionnement social et la qualité de vie subjective de schizophrènes. Ther Comp Cogn 1995 ; 5 :37-43.
11. Corten P. Le concept de " quality de vie" vu à travers la littérature anglo-saxonne. L'information Psychiatrique 1998 ; 9 : 922-32.
12. Divanon F, Delamillieure P, Lehaguez A et al. Comparative evaluation of quality of life in patients with schizophrenia treated with conventional versus atypical neuroleptics: results of a transversal study. L'Encéphale 2006; 32: 459-65.
13. Duyme M, Barbeau J, Jolivet B, Dumar A. Maladie mentale, travail et société. Paris : PUF Diffusion, 1987 : 225-8.
14. Guillard-Bouhet N, Lafay N, Jourdain M, Senon JL. Comparaison de la réadaptation psychosociale et de la qualité de vie des schizophrènes sous neuroleptique classique ou atypique. L'Encéphale 2005 ; 31 : 653-65.
15. Gilles R, Simeoni MC, Auquier P et al. Assessing health-related quality of life in patients suffering from schizophrenia : a comparison of instruments. European Psychiatry 2005; 20: 510-9.
16. Lancon C, Auquier P, Launois R et al. Evaluation de la qualité de vie des patients schizophrènes : validation de la version courte de la QOL. L'Encéphale 2000 ; 26 : 11-6.
17. Lehman AF. Well being of chronic mental health patients: assessing their quality of life. Arch Gen Psychiatry 1983; 40: 369-73.
18. Mahmoud RA, Engelhart L M, Janagap CC et al. Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of life and Resource Use under Custmary Clinical Care Clin Drug Investing. 2004; 24: 275-86.
19. Martin P. Le concept de qualité de vie. Act Med 1999 ; 16 :4-5.
20. Meltzer HV, Burnett S, Bastani B et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry 1990; 41: 892-7.
21. Noordsy DL, O'keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry 1999; 60: 47-53.
22. Revicki DA, Genduso LA, Hamilton S et al Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders : quality of life and clinical outcomes of a randomised clinical trial. Quality of life Research 1999; 8: 417-26.
23. Rossler W, Salize HJ, Cucchiaro G et al. Does the place of treatment influence the quality of life of schizophrenics. Acta Psychiatr Scand 1999; 100: 142-8.
24. Tempier R, Pawliuk N. Influence of new and conventional antipsychotic medication on subject quality of life. Journal of Psychiatry &Neuroscience 2001; 26: 131-6.
25. Voruganti L, Cortese L, Oyewumi L et al. Comparative evaluation of conventional and novel antipsychotic drugs reference to their subtjective tolerability, side effect profit and impact to quality of life. Schizophrenia Res 2000; 43: 135-45.
26. Wehmeir PM, Kluge M, Schneider E et al. Quality of life and subjective well-being during treatment with antipsychotics in outpatientswith schizophrenia. Prog Neuropsychopharmacol Bio Psychiatry 2007; 31: 703-12.
27. Zannotti M.A method for quality of life assessment in psychiatry : the subjective quality of life. Quality of life news letter 1992; 4-6.
28. Zhangab PL, Santosc JM, Newcomerab J et al. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophrenia Research 2004; 71: 137-4